Journal
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES
Volume 9, Issue 6, Pages 575-582Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ehjqcco/qcac056
Keywords
hypertension; renal denervation; relative risk reduction; outcome assessment; cardiovascular risk
Categories
Ask authors/readers for more resources
Renal denervation using radiofrequency has been found to lower blood pressure and reduce cardiovascular events in patients with uncontrolled hypertension. The magnitude of blood pressure reduction and associated risks of cardiovascular events vary among different high-risk subgroups. Model-based projections suggest that radiofrequency renal denervation provides significant clinical benefits for patients with uncontrolled hypertension.
Aims Renal denervation has been shown to lower blood pressure in sham-controlled trials and represents a device-based treatment option for hypertension. We sought to project clinical event reductions after radiofrequency renal denervation using a novel modelling approach. Methods and results The Global SYMPLICITY Registry is a global, prospective all-comer registry to evaluate safety and efficacy after renal denervation. For this analysis, change in office systolic blood pressure from baseline was calculated from reported follow-up in the Global SYMPLICITY Registry. Relative risks for death and other cardiovascular events as well as numbers needed to treat for event avoidance were obtained for the respective blood pressure reductions based on previously reported meta-regression analyses for the full cohort and high-risk subgroups including type 2 diabetes, chronic kidney disease, resistant hypertension, and high basal cardiovascular risk. Average baseline office systolic blood pressure and reduction estimates for the full cohort (N = 2651) were 166 +/- 25 and -14.8 +/- 0.4 mmHg, respectively. Mean reductions in blood pressure ranged from -11.0--21.8 mmHg for the studied high-risk subgroups. Projected relative risks ranged from 0.57 for stroke in the resistant hypertension cohort to 0.92 for death in the diabetes cohort. Significant absolute reductions in major adverse cardiovascular events over 3 years compared with the projected control (8.6 +/- 0.7% observed vs. 11.7 +/- 0.9% for projected control; P < 0.01) were primarily due to reduced stroke incidence. The robustness of findings was confirmed in sensitivity and scenario analyses. Conclusion Model-based projections suggest radiofrequency renal denervation for patients with uncontrolled hypertension adds considerable clinical benefit across a spectrum of different cohort characteristics.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available